Novel Cell
Therapies

Kiadis’ proprietary off-the-shelf NK-cell platform is based on NK-cells from a unique universal donor.

Patient
Focus

Kiadis is focused on patient specific cell-based immunotherapy products for the treatment of life threatening diseases.

K-NK
Pipeline

Kiadis has a pipeline of NK-cell therapies in development to treat blood cancer and solid tumors.

Core Values

We always do the right thing:

  • We put the patient first
  • We are open and honest
  • We help each other
  • We act with a sense of urgency
  • We deliver quality

Press release

Kiadis announces the placement of €5 million convertible bonds with Kreos

01 Oct 2020

Events

Kiadis Pharma Interim Results for the Six Months Ended June 30, 2020

30 Sep 2020

Our uncompromising approach to serve patients, their families and care givers aims to minimize harm and maximize help – delivering personalized treatments for every single patient to offer hope, reduce suffering and provide new life.

Research focus

Kiadis is focused on developing new cancer immunotherapeutics as well as novel adjunctive treatments for patients undergoing hematopoietic stem cell transplants.

Pipeline

Pipeline

We have a pipeline of NK-cell therapies in development as adjunctive therapy for hematopoietic stem cell transplantation and as potential therapeutics for both liquid and solid tumors.

Pipeline

kiadis pipeline image